Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.

Market Cap: N/A
Industry: Pharmaceuticals & Biotechnology
ISIN: CNE100000387

HKD

19.15

1.11 (6.15%)

Feb 16

HKG

View all stocks in this country

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

SciClone Pharmaceuticals (Holdings) Ltd.

Livzon Pharmaceutical Group, Inc.

Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Ocumension Therapeutics

Shandong Boan Biotechnology Co., Ltd.

Cutia Therapeutics

Lepu Biopharma Co., Ltd.

RemeGen Co., Ltd.

Everest Medicines Ltd.

InnoCare Pharma Ltd.

Why is Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. ?

High Management Efficiency with a high ROE of 11.75%

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 9.23

High Debt company with Weak Long Term Fundamental Strength

Flat results in Dec 15

With ROE of 7.53%, it has a Fair valuation with a 0.10 Price to Book Value

The stock is trading at a fair value compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 6.98%, its profits have fallen by -28.3%

Underperformed the market in the last 1 year

The stock has generated a return of 6.98% in the last 1 year, much lower than market (Hang Seng Hong Kong) returns of 18.06%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. for you?

Low Risk, Low Return

Absolute

Risk Adjusted

Volatility

Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.

-100.0%

-0.92

18.75%

Hang Seng Hong Kong

18.06%

0.71

25.51%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

4.06%

EBIT Growth (5y)

-0.25%

EBIT to Interest (avg)

9.23

Debt to EBITDA (avg)

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

1.57

Tax Ratio

16.19%

Dividend Payout Ratio

46.45%

Pledged Shares

Institutional Holding

0.14%

ROCE (avg)

15.88%

ROE (avg)

11.75%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.10

EV to EBIT

0.86

EV to EBITDA

0.65

EV to Capital Employed

0.07

EV to Sales

0.03

PEG Ratio

Dividend Yield

4.77%

ROCE (Latest)

7.89%

ROE (Latest)

7.53%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Sideways

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Not enough Data to analyse Financial Trend

Here's what is working for Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.

Raw Material Cost

Fallen by -19.1% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales